Cargando…
Can the onset of heart failure be delayed by treating diabetic cardiomyopathy?
The pathophysiology of diabetic cardiomyopathy (DC) is not fully understood. This frequently undiagnosed complication of chronic hyperglycemia leads to heart failure (HF). However, it is suggested that an appropriate metabolic control of diabetes at an early stage of this deleterious disease, is abl...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381046/ https://www.ncbi.nlm.nih.gov/pubmed/28396699 http://dx.doi.org/10.1186/s13098-017-0219-z |
_version_ | 1782519859414827008 |
---|---|
author | Marcinkiewicz, Anna Ostrowski, Stanisław Drzewoski, Józef |
author_facet | Marcinkiewicz, Anna Ostrowski, Stanisław Drzewoski, Józef |
author_sort | Marcinkiewicz, Anna |
collection | PubMed |
description | The pathophysiology of diabetic cardiomyopathy (DC) is not fully understood. This frequently undiagnosed complication of chronic hyperglycemia leads to heart failure (HF). However, it is suggested that an appropriate metabolic control of diabetes at an early stage of this deleterious disease, is able to inhibit the development and progression of DC to HF. Recently, it has been postulated that myocardial ischaemia plays an important role in the development of this pathology. Results of the antianginal pharmacological treatment and revascularization are unsatisfactory and reveal a gap in our knowledge and current approaches to treating DC. Most recent studies emphasize the ischaemic component of DC as a key target for therapeutic strategies, which could change its unfavorable history. More stress is put on an early diagnosis of coronary artery disease (CAD), promoting prompt revascularization. Choosing the accurate time of surgical revascularization, with the inclusion of the metabolic background, can ensure complete revascularization with better prognosis. This review will focus on the complexity of DC and summarize contemporary knowledge of treatment strategies for patients with diabetes and CAD. |
format | Online Article Text |
id | pubmed-5381046 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53810462017-04-10 Can the onset of heart failure be delayed by treating diabetic cardiomyopathy? Marcinkiewicz, Anna Ostrowski, Stanisław Drzewoski, Józef Diabetol Metab Syndr Review The pathophysiology of diabetic cardiomyopathy (DC) is not fully understood. This frequently undiagnosed complication of chronic hyperglycemia leads to heart failure (HF). However, it is suggested that an appropriate metabolic control of diabetes at an early stage of this deleterious disease, is able to inhibit the development and progression of DC to HF. Recently, it has been postulated that myocardial ischaemia plays an important role in the development of this pathology. Results of the antianginal pharmacological treatment and revascularization are unsatisfactory and reveal a gap in our knowledge and current approaches to treating DC. Most recent studies emphasize the ischaemic component of DC as a key target for therapeutic strategies, which could change its unfavorable history. More stress is put on an early diagnosis of coronary artery disease (CAD), promoting prompt revascularization. Choosing the accurate time of surgical revascularization, with the inclusion of the metabolic background, can ensure complete revascularization with better prognosis. This review will focus on the complexity of DC and summarize contemporary knowledge of treatment strategies for patients with diabetes and CAD. BioMed Central 2017-04-04 /pmc/articles/PMC5381046/ /pubmed/28396699 http://dx.doi.org/10.1186/s13098-017-0219-z Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Marcinkiewicz, Anna Ostrowski, Stanisław Drzewoski, Józef Can the onset of heart failure be delayed by treating diabetic cardiomyopathy? |
title | Can the onset of heart failure be delayed by treating diabetic cardiomyopathy? |
title_full | Can the onset of heart failure be delayed by treating diabetic cardiomyopathy? |
title_fullStr | Can the onset of heart failure be delayed by treating diabetic cardiomyopathy? |
title_full_unstemmed | Can the onset of heart failure be delayed by treating diabetic cardiomyopathy? |
title_short | Can the onset of heart failure be delayed by treating diabetic cardiomyopathy? |
title_sort | can the onset of heart failure be delayed by treating diabetic cardiomyopathy? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381046/ https://www.ncbi.nlm.nih.gov/pubmed/28396699 http://dx.doi.org/10.1186/s13098-017-0219-z |
work_keys_str_mv | AT marcinkiewiczanna cantheonsetofheartfailurebedelayedbytreatingdiabeticcardiomyopathy AT ostrowskistanisław cantheonsetofheartfailurebedelayedbytreatingdiabeticcardiomyopathy AT drzewoskijozef cantheonsetofheartfailurebedelayedbytreatingdiabeticcardiomyopathy |